On August 29, 2019, Professor Stephen Jane visited XJTU's School of Public Health. Professor Jane is a fellow of the Australian Academy of Health and Medical Sciences, a professor and the dean-designate of the School of Medicine of Monash University, and a research director of Alfred Hospital.

Professor Jane was also invited for a lecture titled Development of novel therapeutics for the Hemoglobinopathies. He introduced a new treatment for β-thalassemia and hemoglobinopathy. Hemoglobinopathy is one of the most common single-gene disorders, which is usually treated with hydroxycarbamide. However, about 30% to 40% patients show intolerance or do not response to it. Based on a series of molecular biological and clinical experiments, Professor Jane proved that PRMT5 inhibitor when used as a targeted medicine, shows great potential in clinical and translational science for hemoglobinopathies treatment.